title: Hyperglycemia in the critically ill.
abstract: Hyperglycemia is frequently seen in acutely ill patients and has historically been viewed as a normal response to stress. Treatment is often not initiated unless blood glucose exceeds 200 to 250 mg/dL. Recent evidence suggests that hyperglycemia is associated with worse outcomes within the population of medical and surgical intensive care units. Hyperglycemia in this population of patients develops from increased gluconeogenesis and insulin resistance. Although the specific mechanisms by which hyperglycemia contributes to poor outcomes are as yet unknown, disruption of normal mitochondrial respiration, direct glucose toxicity, accumulation of asymmetric dimethylarginine, and impairment of immune cell function are among the possibilities implicated. Studies demonstrate that intensive insulin therapy to achieve euglycemia reduces mortality and morbidity in critically ill patients. In addition to recognizing and treating hyperglycemia, it is as important to identify other frequently overlooked factors that contribute to hyperglycemia, such as medications, intravenous fluids, and enteral and parenteral nutrition.
authors: Department of Medicine, Tufts-New England Medical Center and the Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
authors: Colleen
authors: C
authors: Digman
authors: Dara
authors: D
authors: Borto
authors: Stanley A
authors: SA
authors: Nasraway
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D016638:Critical Illness / Q000401:mortality / Q000628:therapy; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D007362:Intensive Care Units; D018529:Nutritional Support
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin